## Edgar Filing: BIOCRYST PHARMACEUTICALS INC - Form 4

BIOCRYST Form 4 May 17, 201	PHARMACEU	FICALS II	NC										
FORM	ΠΔ									OMB A	PPROVA	۹L	
	UNITED	STATES		RITIES shingtor				COMMISSIO	N	OMB Number:	3235	-0287	
Check th												ry 31,	
if no lon subject t Section	o SIAIEN	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES									Expires: 20 Estimated average burden hours per		
Form 4 or Form 5 obligations may continue. See Instruction 1(b). Form 5 obligations may continue. See Instruction Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940										0.5			
(Print or Type	Responses)												
1. Name and A HIGGINS J	Person <sup>*</sup>	2. Issuer Name <b>and</b> Ticker or Trading Symbol					5. Relationship of Reporting Person(s) to Issuer						
		BIOCRYST PHARMACEUTICAI INC [BCRX]					(Check all applicable)						
(Last) (First) (Middle) 2190 PARKWAY LAKE DRIVE			3. Date of Earliest Transaction (Month/Day/Year) 05/13/2010				Officer (give titleOther (specify below)						
			4. If Amendment, Date Original Filed(Month/Day/Year)				6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person						
BIRMING	HAM, AL 35244-							Form filed by Person	у Мо	re than One R	eporting		
(City)	(State)	(Zip)	Tab	le I - Non-	Deriv	ative	Securities A	cquired, Disposed	l of,	or Beneficia	lly Owne	d	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)		Date, if	3. Transactio Code (Instr. 8)	onAcq Disp	posed	(A) or	5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	For (D) (I)	Ownership rm: Direct ) or Indirect str. 4)	7. Nature Indirect Beneficie Ownersh (Instr. 4)	al iip	
				Code V	Amo	ount	(D) Price	(Instr. 3 and 4)					
Reminder: Rep	port on a separate line	for each cla	ass of sec	urities bene	eficiall	ly owr	ed directly	or indirectly.					
					ir re	nform equir	ation cont ed to resp	spond to the collection of the	m ai orm	re not	SEC 1474 (9-02)		

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Ar
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transactio	orDerivative	Expiration Date	Underlying Se
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)

number.

## Edgar Filing: BIOCRYST PHARMACEUTICALS INC - Form 4

(Instr. 3)	Price of Derivative Security		(Month/Day/Year)	(Instr.	str. 8) Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		d of			
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title
Non-Qualified Stock Option $(1)$	\$ 7.01	05/13/2010		А		15,000		06/14/2010(2)	05/13/2020	Common Stock

## **Reporting Owners**

<b>Reporting Owner Name / Address</b>	Relationships							
	Director	10% Owner	Officer Other					
HIGGINS JOHN L 2190 PARKWAY LAKE DRIVE BIRMINGHAM, AL 35244-	Х							
Signatures								
/s/ Michael Richardson, by power of attorney	of	05/17/2010						
**Signature of Reporting Person		Date						

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Automatic non-employee director grant
- (2) The option vests 1/12 per month for 12 months, beginning on June 14, 2010.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.